Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

OPSENS TO HOST THIRD QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY, JULY 14

T.OPS

Conference call to be conducted at 11:00 am ET

Logo (CNW Group/OpSens Inc.)

QUEBEC CITY, QC, July 7, 2022 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, will report financial results for its third quarter of fiscal year 2022, ended May 31st, on Thursday, July 14, before the open of the market. The Company has scheduled a conference call the same day, at 11:00 AM ET, to review the results.

Interested parties can access the conference call by dialing 1-833-756-0865 or 1-412-317-5754 or can listen via a live webcast, available in the Investors section of the Company's website at https://opsens.com/investors/ or at https://app.webinar.net/y85X9w0qkGv.

A teleconference replay of the call will be available in the Investors section of the Company's website at https://opsens.com/investors/.

About OpSens Inc. (www.OpSens.com or www.OpSensmedical.com)

OpSens focuses mainly on interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesion access. The OptoWire has been used in the diagnosis and treatment of over 150,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

SOURCE OpSens Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2022/07/c1852.html

Tags: